Connect with us

BioPharma

Iqstel Inc (OTCMKTS: IQST) Powerful Run Northbound as EV Motorcycle Manufacture Reports Record Revenues and looks to Up List to a Major Exchange

Published

on

Iqstel Inc (OTCMKTS: IQST) is making a powerful move northbound off its base at $0.50 in recent trading after the Company announced record Q3 revenues. Year to date the Company reported $46.84 Million compard to $29.44 for the same period last year. This year IQST revenues continue to rise; in Q1 the Company reported $14.19 Million in Q1, $16.12 Million in Q2, $16.51 Million in Q3. and expect to hit net income positive by next quarter. Having graduated from one OTC Markets marketplace to the next achieving an OTCQB certification and then an OTCQX certification and incorporating the required corporate governance to include an Independent Board of Directors and an Independent Audit Committee, the distance from here to a Nasdaq listing is not too far a reach. 

Also last week IQST reported the manufacturing of its EVOSS electric motorcycles is scheduled to begin next week. The electric motorcycles are slated for delivery to the USA, Latin American and the EU. The first electric motorcycles are expected to roll off the production line before the end of this FY. The first production run includes the EVOSS 250, 350 and 450 models equipped with 2, 3, and 4 Kw motors.  All models come with a 72 Volt, 50 AmpH battery. The Company’s vision is to become a major player in EV Motorcycle market within Latin America, and the EU over the next three years. The company has presence in 15 countries, and its products and services are used in several industries as Telecommunications, Electric Vehicle (EV), Financial Services, Chemical and Liquid Fuel Distribution Industries. IQSTEL announced on February 17th 2021 that it became a Debt Free Company and is now completely debt free with no Convertible Notes, Warrants, Promissory Notes or Settlement Agreements from its Balance Sheet.  

Iqstel Inc (OTCMKTS: IQST) is a US-based publicly-listed company holding an Independent Board of Directors and Independent Audit Committee offering leading-edge services through its two business divisions and each of them with independent brands. The B2B division, Brand IQSTelecom offering Telecommunications, Internet of Things, Technology and Blockchain platforms services, the target market for the B2B division is Global Markets. The B2C division, Brand EVOSS offering EV Electric Motorcycles, Fintech Ecosystem, the target market for this business division is Latin America, and the Spanish speakers in the USA. The company has presence in 15 countries, and its products and services are used in several industries as Telecommunications, Electric Vehicle (EV), Financial Services, Chemical and Liquid Fuel Distribution Industries. IQSTEL announced on February 17th 2021 that it became a Debt Free Company and is now completely debt free with no Convertible Notes, Warrants, Promissory Notes or Settlement Agreements from its Balance Sheet. 

Earlier this month IQST reported the manufacturing of its EVOSS electric motorcycles is scheduled to begin next week. The electric motorcycles are slated for delivery to the USA, Latin American and the EU. The first electric motorcycles are expected to roll off the production line before the end of this FY. The first production run includes the EVOSS 250, 350 and 450 models equipped with 2, 3, and 4 Kw motors.  All models come with a 72 Volt, 50 AmpH battery. 

The EVOSS electric motorcycle is a custom design with a max range up to 150 Km per battery charge, a max speed up to 90 Km/h, and a max torque of 140 N – varying based on model. The first shipments are intended to trial and establish in country dealer networks and support within each destination country. The Company’s vision is to become a major player in EV Motorcycle market within Latin America, and the EU over the next three years.   

Microcapdaily first reported on IQST in February 2000 as the stock was moving up over a dime stating at the time: “IQST has seen a surge in price and trading volume after the Company announced it has reached a definitive agreement with Labrys Fund extending the terms of the previous promissory note thereby stopping further conversions. This is huge news for IQST as the debt conversions was the primary factor in keeping the pps so low. IQST has already attracted a significant shareholder base that has been accumulating. The Company is an emerging player in the international telecommunications business and already boasts very significant revenues.

iQSTEL Inc. (IQST) Stock Message Board - InvestorsHub

To Find out the inside Scoop on IQST Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

IQST

IQSL is doing big numbers and has never been in a greater financial position and with better financial performance resulting from the successful execution of its business plan. iQSTEL has been a debt-free company since February 2021. No Reg-A shares have been sold since March 2021, and the quarter-after-quarter net income improvements put the company on a clear track to reach break-even in the short term. Having graduated from one OTC Markets marketplace to the next achieving an OTCQB certification and then an OTCQX certification and incorporating the required corporate governance to include an Independent Board of Directors and an Independent Audit Committee, the distance from here to a Nasdaq listing is not too far a reach. 

FINANCIALS YTD Q3 FY-2021 vs YTD Q3-FY-2020:  REVENUE: $46.84 Million YTD FY-2021 vs $29.44 Million YTD FY-2020, a 59% increase. GROSS PROFIT: $1.37 Million YTD FY-2021 vs $0.70 Million YTD FY-2020, a 95% increase. DILUTIVE DEBT (Convertible notes, Warrants, and Derivative liabilities): ZERO YTD FY-2021 vs $8.43 Million YTD FY-2021 

FY-2021 POSITIVE FINANCIAL TREND: REVENUE: $14.19 Million in Q1, $16.12 Million in Q2, $16.51 Million in Q3. NET INCOME (LOSS): $(1.87) Million in Q1, $(1.11) Million in Q2, $(0.11) Million in Q3. 

EV Electric Motorcycles: We completed the design for the first Models 250, 350, 450 (2,3,4 Kw, and Batteries 50AmpH x 72Volt), and we are starting the manufacturing of the first batch this week, which we expect to begin rolling off the production line by next month. 

EV Batteries: We completed the High Power Batteries design and specs for Revolt Motorcycles (ALYI, Modus) and we are now in negotiations with ALYI about the commercial terms. 

Fintech: We completed the Global Money One ecosystem, however, we have postponed the Global Commercial Launching and the delivery of the MAXMO contest winners as we are working on the back-end improvement of our reconciliation process. We will be announcing the Global Commercial launching and the MAXMO contest winners soon. 

The Company recently hired Tony Abdo as CEO EVOSS Division and Senior Business Development VP for Internet of Things and Blockchain Platforms: Mr. Abdo is on a fast track and already working on an expedited commercial plan to close business proposals already in progress. Mr. Abdo is also developing the in-country dealer network for our EVOSS EV Motorcycles. 

in the Coming year the company plans to potentially surpass the Forecast for FY-2021: We are on the home stretch to accomplish our Forecast of $60.5 Million for this FY. Management is confident about reaching this business goal, and still working to surpass it. Other catalysts include the Global Commercial Launching of MAXMO. The EVOSS EV Motorcycles will roll off the production line. Updates on our M&A Campaign and Nasdaq Up-listing progress. 

 For More on IQST Subscribe Right Now!

IQST is making a powerful move northbound off its base at $0.50 in recent trading after the Company announced record Q3 revenues. Year to date the Company reported $46.84 Million compard to $29.44 for the same period last year. This year IQST revenues continue to rise; in Q1 the Company reported $14.19 Million in Q1, $16.12 Million in Q2, $16.51 Million in Q3. and expect to hit net income positive by next quarter. Having graduated from one OTC Markets marketplace to the next achieving an OTCQB certification and then an OTCQX certification and incorporating the required corporate governance to include an Independent Board of Directors and an Independent Audit Committee, the distance from here to a Nasdaq listing is not too far a reach. Also last week IQST reported the manufacturing of its EVOSS electric motorcycles is scheduled to begin next week. The electric motorcycles are slated for delivery to the USA, Latin American and the EU. The first electric motorcycles are expected to roll off the production line before the end of this FY. The first production run includes the EVOSS 250, 350 and 450 models equipped with 2, 3, and 4 Kw motors.  All models come with a 72 Volt, 50 AmpH battery. The Company’s vision is to become a major player in EV Motorcycle market within Latin America, and the EU over the next three years. The company has presence in 15 countries, and its products and services are used in several industries as Telecommunications, Electric Vehicle (EV), Financial Services, Chemical and Liquid Fuel Distribution Industries. IQSTEL announced on February 17th 2021 that it became a Debt Free Company and is now completely debt free with no Convertible Notes, Warrants, Promissory Notes or Settlement Agreements from its Balance Sheet. We will be updating on IQST when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with IQST.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

sclosure: we hold no position in IQST either long or short and we have not been compensated for this article.

BioPharma

Advancing Medical Frontiers: Elutia Inc.’s(NASDAQ: ELUT) Strategic Vision in a $600 Million Market

Published

on

Elutia Inc (NASDAQ: ELUT) shares bolstered a whopping 33% today as the company recently shared that they’ve secured about $10.5 million in funding through a private investment round. If all the warrants are cashed in as part of this funding, the total could go up to $26.2 million.

Latest Changes:

Just last week, Aziyo Biologics changed its name to Elutia Inc. Following this change, Elutia made an announcement about selling its Orthobiologics business unit to Berkeley Biologics, a subsidiary of GNI Group Ltd. This move is set to bring in a substantial amount of cash, totalling up to $35 million for Elutia. This sum includes a notable upfront payment of $15 million, plus additional potential earnings of up to $20 million over five years. The deal is expected to be finalized in the fourth quarter of 2023.

This sale is a big step for Elutia, especially in the realm of drug-eluting biomatrix technology (DEB). Elutia is actively seeking approval from the FDA for their main product, CanGaroo RM. This product utilizes innovative biomatrix technology with antibiotics rifampin and minocycline (RM), providing long-term protection for cardiac pacemakers and defibrillators. This tackles a huge market estimated to be worth around 600 million. Elutia is aiming to introduce CanGaroo RM to the market in the first half of 2024.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Standard Of Care:

Medtronic (NYSE: MDT) stands as the exclusive provider of the antibiotic envelope within the current market. This envelope is crafted using synthetic mesh infused with antibiotics. Back in 2014, Medtronic acquired this technology, making a strategic investment of up to $200 million. Primarily intended for Cardiac Implantable Electronic Device (CIED) revision procedures, this product boasts estimated annual sales in the range of $250 to $300 million.

However, despite its market presence and revenue generation, the Medtronic antibiotic envelope has notable limitations. While it effectively combats infections, its synthetic composition renders it less effective in supporting wound healing. Moreover, it poses challenges in accommodating larger devices like Subcutaneous Implantable Defibrillators (SCID).

Drug-eluting biomatrix (DEB):

Drug-eluting biomatrix (DEB) involves a specialized approach to drug delivery using a biomatrix as a carrier or platform. In simple terms, it’s a technique where a biomaterial matrix, often a biocompatible polymer or similar substance, is used to release drugs in a controlled and targeted manner.

The biomatrix acts as a support structure that can hold and gradually release drugs or therapeutic agents at a specific site in the body, typically over an extended period. This is particularly useful in medical applications where a localized and sustained delivery of medication is necessary.

For instance, in the context of Elutia’s CanGaroo RM, a biomatrix incorporating antibiotics rifampin and minocycline is used to provide prolonged protection for cardiac pacemakers and defibrillators. The biomatrix slowly releases these antibiotics at the surgical site, preventing infections and promoting healing.

DEB technology is gaining traction because it enhances treatment efficiency by ensuring the drug is delivered directly to the target area, minimizing side effects, and optimizing therapeutic outcomes. It’s a promising approach in the field of medical advancements, especially in areas like cardiology, oncology, and orthopedics.

Post-mastectomy Breast Reconstruction:

On top of this, the company also has plans to develop an RM version of its SimpliDerm biomatrix tailored for breast reconstruction procedures. The rate of infections after this surgery is quite high, more than 10%, highlighting a big medical need in a market valued at over $500 million. Elutia is stepping up to address this issue by developing SimpliDerm® RM, which incorporates their unique DEB technology. The funds raised through the private investment round (PIPE) and the sale of the Orthobiologics business unit will not only boost Elutia’s efforts in advancing their drug-eluting biomatrix products for the cardiac pacemaker and defibrillator market, but also for post-mastectomy breast reconstruction.

What’s next:

As mentioned earlier, their biomatrix platform serves two major markets. CanGaroo RM, their upcoming product, is slated for a 1H of 2024 market release and is poised to be a pioneer in a $600 million market. Furthermore, their SimpliDerm RM product utilizes the same proprietary antibiotic-eluting technology found in CanGaroo RM, which serves a 1.6B market according to their presentation deck. They aim to secure an IDE by Q4 2024, and upon achieving these milestones, they plan to venture into neurostimulator markets, particularly in pain management, to further drive their growth.

We will update you on ELUT when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by sasint from Pixabay

Continue Reading

BioPharma

ZyVersa Therapeutics’ (NASDAQ: ZVSA) Breakthrough: A Super Tool for Tackling Inflammation in ALS and Beyond

Published

on

ZyVersa Therapeutics (NASDAQ: ZVSA) had a spectacular day on the market, with its stock surging by almost 50% following a significant announcement about one of their promising drug candidates, IC-100. This drug is designed to combat inflammation in the context of Inflammatory Diseases, and the latest data is incredibly promising. For those who are new to this field of investment, we’ve taken the liberty of rephrasing the press release in simpler terms.

The Release:

When you’re dealing with diseases like ALS that affect your brain and nerves, shutting down the inflammasome pathway NLRP3 (a multi-protein that regulates the immune system and inflammatory signaling), is not enough.

To address this, ZyVersa is working on something called Inflammasome ASC Inhibitor IC-100. It’s like a super tool designed to block not just NLRP3 but a bunch of other inflammasome pathways too – up to 12 of them. This helps keep inflammation in check, whether it’s in the central nervous system (CNS) or other parts of the body where inflammation is causing problems.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

In a recent paper published in Frontiers in Immunology, they pointed out that focusing only on NLRP3 might not do the trick when it comes to calming CNS inflammation in ALS and similar diseases. They did experiments with cells and even used mice to back up their point. Turns out, just targeting NLRP3 didn’t stop the release of those pesky proinflammatory chemicals or the damage they were causing in the spinal cord.

The authors of the paper basically said, “Maybe we should aim to tackle multiple inflammasome pathways when it comes to diseases like ALS, where lots of inflammasomes are going haywire.”

The CEO and president at ZyVersa, Stephen C. Glover mentioned “Our research shows that to really put the brakes on inflammation driven by multiple inflammasomes, we need more than just NLRP3 inhibition.” He added that IC-100 is like a superhero in the world of inflammation control. It stops the formation of different types of inflammasomes, preventing the start of the inflammation chain reaction, and also puts a halt to something called ASC specks, which keep the inflammation going. You can dive deeper into how IC 100 works by checking out their website here.

So, in plain speak, ZyVersa is cooking up a promising solution for folks dealing with inflammation-related problems, especially those tied to the brain and nerves. They’re not just focusing on one troublemaker; they’re going after a whole gang to keep things under control.

Overall ZyVersa is a company on a mission to create groundbreaking treatments for kidney and inflammatory diseases, and IC-100 could help them in this mission.

We will update you on ZVSA when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by swiftsciencewriting from Pixabay

Continue Reading

BioPharma

Creative Medical Technology NASDAQ: CELZ) Major Breakthrough: Allogeneic Cell Line Paves the Way for Diabetes Treatment

Published

on

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) has recently seen a substantial intraday gain of over 15% in its share price. Despite the absence of any recent news or filings, this surge could suggest significant progress in the realm of allogeneic cell therapy.

Background:

The company is known for its regenerative approaches in various medical areas, including immunotherapy, endocrinology, urology, gynecology, and orthopedics, and made a significant announcement. In the fourth quarter of 2022,They successfully developed a new allogeneic cell line called AlloStem™. AlloStem™ is derived from human perinatal tissue and includes a Master Cell Bank and a Drug Master File. Now, with FDA approval, their program, known as CELZ-201, is being used in an early clinical trial for type 1 diabetes and will continue to be developed for both type 1 and type 2 diabetes treatment.

Additionally, the company is using the AlloStem™ line for its StemSpine® procedure to help treat chronic back pain. They report remarkable results, including over a 90% reduction in narcotic usage, more than an 80% reduction in pain scores, and over a 50% reduction in the Oswestry score in patients treated with AlloStem™.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Allogeneic Cell Therapy:

Allogeneic Cell Therapy is a treatment that uses cells from healthy donors to treat patients with otherwise untreatable diseases. These cells can come from various sources, like bone marrow, blood, or umbilical cord blood. This approach shows great promise in the medical field.

Allogeneic cell therapy offers potentially curative options for patients when traditional treatments fall short. While still a relatively new field, ongoing research into allogeneic cell therapies holds great potential for patients suffering from these diseases. Companies like Argan Inc. are also exploring the benefits of allogeneic cells.

With FDA approval and ongoing clinical trials, Creative Medical Technology’s recent developments open doors to innovative treatments that could significantly enhance the lives of those dealing with diabetes and other diseases. The global market for allogeneic cell therapy reached $255.6 million in 2022 and is expected to grow at a rate of 27.4% from 2023 to 2030, emphasizing the importance of continued research. As the company remains dedicated to medical innovation, their efforts have the potential to improve the health outcomes of people worldwide.

Latest Release:

The company recently shared key updates on its financial status and drug pipeline for Q3 2023. The biotech company, known for its regenerative medical solutions, reported being debt-free with $14.6 million in cash and $14.4 million in working capital, sufficient to cover expenses through 2024.

Their advancements in treating type 1 diabetes include FDA clearance for a groundbreaking clinical trial using CELZ-201 (AlloStem™). The company obtained Institutional Review Board approval and partnered with Syneos Health for this study. They also filed for Orphan Drug Designation to tackle brittle type 1 diabetes.

Promising results emerged from the CELZ-001 treatment for type 2 diabetes, demonstrating substantial reductions in insulin requirements with no safety concerns.

A pilot study on the StemSpine® procedure, using donor cells (AlloStem), showed impressive reductions in narcotic usage, pain scores, and improved functionality for chronic lower back pain patients.

Creative Medical Technology’s ImmCelz platform proved efficient, requiring fewer donor cells and yielding high-quality results.

They also collaborated with Greenstone Biosciences Inc. to develop a human-induced pluripotent stem cell (iPSC) pipeline, iPScelzTM, aimed at expediting drug discovery. The development of this cell line is expected to save the company two to three years in research and development time, along with associated expenses. Additionally, it will accelerate its drug discovery program by leveraging artificial intelligence.

We will update you on CELZ when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by stevepb from Pixabay

 

 

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.